Immuneel Therapeutics announced the successful close of its ₹100 crore plus Series B financing. The round saw participation from new investors, including Singularity AMC, Rainmatter by Zerodha, and several High-Net-Worth Individuals, alongside strong continued support from existing investors, including Kiran Mazumdar-Shaw, Eight Roads Ventures, and F-Prime Capital.
The financing will directly fund key strategic priorities: scaling Immuneel’s GMP manufacturing capacity, advancing its next-generation deep-tech cell and gene therapy pipeline toward clinical milestones, supporting the commercialisation of Qartemi, and accelerating international market entry across the Asia Pacific and the Middle East.
Following the successful commercial launch of Qartemi, approved CAR-T therapy for Non-Hodgkin Lymphoma, Immuneel Therapeutics is now extending its reach into high growth emerging markets and progressing clinical co-development partnerships in Australia and Southeast Asia. The company operates India’s first international standard CAR-T platform to deliver world-class therapies at a fraction of the Western costs.
Kiran Mazumdar-Shaw, Founder of Immuneel Therapeutics, commented: “This company was founded with the belief that advanced cell therapies should not remain confined to a small segment of patients or a handful of geographies. This fundraise strengthens our ability to build a globally competitive CAR-T platform from India, combining deep science, scalable manufacturing and significantly improved affordability. We believe India can play a meaningful role in shaping the future of cell and gene therapy for the world.”
Amit Mookim, Chief Executive Officer of Immuneel Therapeutics, added: “Qartemi’s commercialisation proved we can deliver world-class CAR-T outcomes at a fraction of Western costs. This Series B financing accelerates what comes next: a bold international expansion and a next-generation pipeline that will redefine how cell therapies reach patients globally. We are not just building a company- we are building a new global standard of care, from India.”
Aravind Viswanathan, Senior Operating Partner at Singularity AMC, stated: “CAR-T cell therapy represents one of the most consequential breakthroughs in modern oncology- the ability to engineer a patient’s own immune cells to precisely target and eliminate cancer is a paradigm shift that was, until recently, accessible only to patients in the wealthiest corners of the world. Immuneel is changing that. What excites us most is the breadth of their pipeline: from expanding into new blood cancer indications to next generation modalities that could dramatically reduce the cost and complexity of treatment. Each of these advances has the potential to extend lifesaving therapy to tens of thousands of patients in India and beyond, who currently have no access to it. We are proud to partner with this world-class team as they disrupt the market and scale their premium-outcome therapeutics globally.”
Nithin Kamath, Founder & CEO at Zerodha and Rainmatter, commented: “We’re living a moment where biotech innovations are genuinely changing what’s possible and we’re excited to support Immuneel who are bringing Cell and gene therapies, including CAR-T to Indian patients with a focus on outcomes and accessibility. We believe in supporting innovations that create deep, long-term societal impact. Immuneel’s mission to bridge the accessibility gap for lifesaving cell and gene therapies aligns perfectly with our vision, and we are excited to back their journey towards equitable healthcare and global expansion.”
